Sprint Bioscience has entered into a research collaboration with the Experimental Drug Development Centre (EDDC) in Singapore to expand Sprint Bioscience's MASH (Metabolic dysfunction-associated steatohepatitis) program into inflammatory diseases.

Sprint Bioscience has entered into a research collaboration with the Experimental Drug Development Centre (EDDC) in Singapore to expand Sprint Bioscience's MASH (Metabolic dysfunction-associated steatohepatitis) program into inflammatory diseases. Under the collaboration, compounds developed by Sprint Bioscience in the program will be evaluated by EDDC - Singapore's national platform for drug discovery and development and part of the...

Following the evaluation, EDDC will have the option to take over and further develop the program. Any future revenues will be shared between Sprint Bioscience and EDDC based on how much each party has invested in the program.

Read more about the collaboration in the press release or on EDDC website.